Get the Stockscreener App
4.08
6.25%
0.24
Pre-market:
4.06
-0.02
-0.49%
Nrx Pharmaceuticals Inc stock is traded at $4.08, with a volume of 756.67K.
It is up +6.25% in the last 24 hours and up +24.39% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$3.84
Open:
$3.9
24h Volume:
756.67K
Relative Volume:
0.61
Market Cap:
$174.63M
Revenue:
$1.23M
Net Income/Loss:
$-28.62M
P/E Ratio:
-2.5991
EPS:
-1.5698
Net Cash Flow:
$-14.11M
1W Performance:
-5.77%
1M Performance:
+24.39%
6M Performance:
+106.06%
1Y Performance:
+18.60%
1-Day Range:
$3.90
$4.09
1-Week Range:
$3.65
$4.40
52-Week Range:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
4.08 | 174.63M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | H.C. Wainwright | Buy |
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRXP Stock Price, Quote & Chart - ChartMill
NRXP News | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Study finds IV ketamine shows higher remission rates than esketamine - Investing.com UK
Study finds IV ketamine shows higher remission rates than esketamine By Investing.com - Investing.com South Africa
NRx Pharmaceuticals announces proposed public stock offering - MSN
NRx Pharmaceuticals notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - Investing News Network
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - The Manila Times
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by - GlobeNewswire
Depression study: IV ketamine patients remitted more than nasal esketamine - Stock Titan
NRx Pharmaceuticals Announces Underwriting Agreement and Public Offering of Common Stock - Minichart
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option - Investing News Network
NRx Pharmaceuticals closes $22.3M public offering - Investing.com UK
NRx Pharmaceuticals Announces $20 Million Public Stock Offering - TipRanks
NRx Pharmaceuticals closes $22.3M public offering By Investing.com - Investing.com India
NRX Pharmaceuticals Inc. announced the successful completion of its public offering of common stock, raising a total of $22.3 million. - Bitget
NRX Pharmaceuticals Closes $22.3 Million Stock Offering - marketscreener.com
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option - The Manila Times
NRx Pharmaceuticals Prices $3.50 Stock Offering to Raise ~$18.8 Million; BTIG Leads - TradingView
NRx Pharmaceuticals (NASDAQ: NRXP) closes $22.3M stock sale - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 - GlobeNewswire
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
NRX Pharmaceuticals Prices Public Offering of 5.7 Million Shares - Moomoo
NRx Pharmaceuticals Shares Drop After $20M Public Offering Prices - Moomoo
NRx Pharmaceuticals Plans Underwritten Public Stock Offering - The Globe and Mail
NRx Pharmaceuticals (NASDAQ: NRXP) sells 5.7M shares at $3.50 - Stock Titan
NRXP: Lucid Capital Manages Successful Offering - GuruFocus
NRx Pharmaceuticals announces pricing of public offering of common stock - MSN
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock - Investing News Network
NRx Pharmaceuticals (NRXP) stock fell 19% after hours on Tuesday: Here's why - MSN
NRx Pharmaceuticals prices $20M public offering at $3.50 By Investing.com - Investing.com Australia
NRx Pharmaceuticals prices $20M public offering at $3.50 - Investing.com
NRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 Million - Quiver Quantitative
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock - Benzinga
Biotech NRx Pharmaceuticals prices $20M stock sale for working capital - Stock Titan
NRx Pharmaceuticals Announces Proposed Public Offering of Common Stock on Nasdaq - Minichart
NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why - Benzinga
Why is NRX Pharmaceuticals stock sliding today? By Investing.com - Investing.com Canada
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):